WuXi wraps up construction on a new biologics shop

China's WuXi PharmaTech ($WX) has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area. The new facility is right next to the CRO's preclinical safety testing operation, and WuXi expects it to come online this summer. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.